Supplementary Table S2. Incidence of most common individual AEs considered treatment-related during the core and OLE studies among the OLE study population (i.e., 1 or more events occurring in ≥ 5% of patients)

	LAN–LAN group (n=41)			PBO–LAN group (n=47)	
	Core study	OLE study	Core study and OLE studies (pooled)	Core study	OLE study
Diarrhoea	11 (26.8)	2 (4.9)	12 (29.3)	4 (8.5)	10 (21.3)
Abdominal pain	7 (17.1)	0	7 (17.1)	1 (2.1)	1 (2.1)
Cholelithiasis	4 (9.8)	3 (7.3)	6 (14.6)	3 (6.4)	1 (2.1)
Hyperglycemia	3 (7.3)	1 (2.4)	4 (9.8)	0	0
Flatulence	3 (7.3)	1 (2.4)	3 (7.3)	2 (4.3)	0
Injection site pain	2 (4.9)	1 (2.4)	3 (7.3)	1 (2.1)	1 (2.1)
Steatorrhea	2 (4.9)	0	2 (4.9)	0	3 (6.4)

Data are number (%) of patients with an AE while receiving lanreotide Autogel 120 mg. Adverse events were defined according to the Medical Dictionary for Regulatory Activities version 16.0.
LAN–LAN group, patients receiving lanreotide Autogel in core study as well as the OLE study; OLE, open-label extension; PBO–LAN, patients receiving placebo in the core study before crossing over to lanreotide in the OLE study.